Validation of MoCA-B and MoCA-Blind for Screening Cognitive Decline

NCT07846839 — Not yet recruiting, 124 participants, Universidade Federal do Rio Grande do Norte

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

Validation of the Brazilian Version of the Montreal Cognitive Assessment - Basic (MoCA-B) and Montreal Cognitive Assessment - Blind (MoCA-Blind) for Screening Cognitive Decline

Registry	NCT07846839
Status	Not yet recruiting
Study type	Observational
Enrollment	124 (Estimated)
Sponsor	Universidade Federal do Rio Grande do Norte (Other); collaborators: Federal University of São Paulo, Universidade Federal de Goias, Universidade Estadual de Goiás, Universidade Federal do Rio Grande (FURG)
Conditions	Neurocognitive Deficit
Dates	start 2026-10-01 (estimated), primary completion 2027-03-01 (estimated), completion 2027-03-01 (estimated), first posted 2026-09-29, last updated 2026-09-29

-Summary

The objective of this observational study is to assess the efficacy of two neuropsychological tests (MoCA-B and MoCA-Blind) in detecting cognitive decline in older adults. The main questions it aims to answer are:

Can the results obtained by older adults on the MoCA-B distinguish between those with and without cognitive decline? Can the results obtained by older adults on the MoCA-Blind distinguish between those with and without cognitive decline?

Participants will be required to: 1. Complete a sociodemographic questionnaire; 2. Undergo a visual acuity test; 3. Complete the Pfeffer and IQCODE scales; and 4. Complete the MMSE, MoCA-B, and MoCA-Blind.

Expand all sections · Collapse all

+Arms and interventions

Arm	Type	Interventions	Description
older adults with cognitive decline and without visual impairment
older adults without cognitive decline (healthy) and without visual impairment
older adults with cognitive decline and with visual impairment
older adults without cognitive decline and with visual impairment

+Outcome measures

Primary outcomes

Optimal cut-off score for the MoCA-B and MoCA-Blind [Assessed at baseline (Day 0)]: The scores obtained by the participants (0 to 30) will be used to calculate the ROC curve and determine the optimal cutoff point (highest sensitivity and specificity) to distinguish between cognitive decline and healthy individuals.

+Eligibility

Sex: All, ages: 60 Years to any, accepts healthy volunteers

* Inclusion Criteria
* Older adults aged 60 and over;
* Exclusion Criteria
* Participants under 60 years of age
* Participants with a prior neuropsychological, neurological, or psychiatric diagnosis that could negatively influence assessment results, such as schizophrenia, stroke within the last three months, intellectual disability, etc
* Participants with self-reported or diagnosed hearing impairment (hearing loss or deafness) that is not corrected by hearing aids.